TET2 binds and activates WT1 target genes by increasing the 5hmC levels at the promoter regions of these specific sites in normal HSC, and therefore TET2 inhibits leukemia proliferation in a WT1-dependent manner [81]. The gene discussed is WT1; the disease is leukemia.